Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$177.80
1.550.88%
al cierre: -
$178.23
0.430.24%
After hour: 6:37 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Johnson & Johnson ha un obiettivo di prezzo di consenso pari a $172.37, stabilito in base alle ultime valutazioni degli analisti di 19. Le ultime 3 valutazioni degli analisti sono state rilasciate da Barclays, RBC Capital y Guggenheim il julio 17, 2025. Con un obiettivo di prezzo medio di $176 tra le Barclays, RBC Capital y Guggenheim, c'è un implicito -1.25% downside per Johnson & Johnson da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Barclays
RBC Capital
Guggenheim
UBS
Morgan Stanley
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Johnson & Johnson
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/17/2025 | -1.25% | Barclays | $165 → $176 | Maintains | Equal-Weight | |||
07/17/2025 | 3.8% | RBC Capital | $181 → $185 | Maintains | Outperform | |||
07/17/2025 | -6.3% | Guggenheim | $164 → $167 | Maintains | Neutral | |||
07/17/2025 | 6.6% | UBS | $180 → $190 | Maintains | Buy | |||
07/17/2025 | -1.25% | Morgan Stanley | $171 → $176 | Maintains | Equal-Weight | |||
07/17/2025 | -1.81% | B of A Securities | $161 → $175 | Maintains | Neutral | |||
07/10/2025 | -4.06% | Morgan Stanley | $169 → $171 | Maintains | Equal-Weight | |||
06/05/2025 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
05/13/2025 | -14.16% | Leerink Partners | $169 → $153 | Downgrade | Outperform → Market Perform | |||
04/17/2025 | -7.42% | Barclays | $166 → $165 | Maintains | Equal-Weight | |||
04/16/2025 | -7.98% | Raymond James | $162 → $164 | Maintains | Outperform | |||
04/16/2025 | -5.18% | Morgan Stanley | $164 → $169 | Maintains | Equal-Weight | |||
04/16/2025 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/14/2025 | -9.11% | Raymond James | $165 → $162 | Maintains | Outperform | |||
04/10/2025 | -10.79% | B of A Securities | $171 → $159 | Maintains | Neutral | |||
04/09/2025 | -7.98% | Morgan Stanley | $163 → $164 | Maintains | Equal-Weight | |||
04/09/2025 | -3.5% | Goldman Sachs | $157 → $172 | Upgrade | Neutral → Buy | |||
04/03/2025 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/02/2025 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
04/02/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/12/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/10/2025 | — | Guggenheim | — | Reiterates | Neutral → Neutral | |||
03/05/2025 | -4.06% | B of A Securities | $159 → $171 | Maintains | Neutral | |||
02/19/2025 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
02/03/2025 | -6.86% | Guggenheim | $162 → $166 | Maintains | Neutral | |||
01/28/2025 | -6.86% | Barclays | $159 → $166 | Maintains | Equal-Weight | |||
01/23/2025 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
01/23/2025 | -8.55% | Morgan Stanley | $175 → $163 | Maintains | Equal-Weight | |||
01/23/2025 | -13.03% | Stifel | $170 → $155 | Maintains | Hold | |||
01/23/2025 | -5.18% | Leerink Partners | $182 → $169 | Maintains | Outperform | |||
01/23/2025 | -14.72% | Wells Fargo | $166 → $152 | Maintains | Equal-Weight | |||
01/23/2025 | -7.42% | Raymond James | $170 → $165 | Maintains | Outperform | |||
01/23/2025 | -10.79% | B of A Securities | $160 → $159 | Maintains | Neutral | |||
01/17/2025 | -10.23% | B of A Securities | $166 → $160 | Maintains | Neutral | |||
12/11/2024 | -1.81% | Citigroup | $185 → $175 | Maintains | Buy | |||
12/10/2024 | -6.86% | B of A Securities | → $166 | Reinstates | → Neutral | |||
11/15/2024 | 6.6% | Wolfe Research | → $190 | Initiates | → Outperform | |||
11/06/2024 | -9.11% | Guggenheim | $156 → $162 | Maintains | Neutral | |||
10/16/2024 | 3.8% | Citigroup | $180 → $185 | Maintains | Buy | |||
10/16/2024 | -6.86% | Wells Fargo | $163 → $166 | Maintains | Equal-Weight | |||
10/16/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/16/2024 | 1.55% | RBC Capital | $178 → $181 | Maintains | Outperform | |||
10/16/2024 | -1.81% | Morgan Stanley | $169 → $175 | Maintains | Equal-Weight | |||
10/10/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/08/2024 | -0.13% | RBC Capital | $175 → $178 | Maintains | Outperform | |||
09/30/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/23/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/20/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
09/19/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/09/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
09/03/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
08/05/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
07/30/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
07/30/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
07/23/2024 | -15.84% | Daiwa Capital | $160 → $150 | Downgrade | Outperform → Neutral | |||
07/19/2024 | -13.03% | Goldman Sachs | $160 → $155 | Maintains | Neutral | |||
07/18/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
07/18/2024 | 3.8% | TD Cowen | $195 → $185 | Maintains | Buy | |||
07/18/2024 | -5.18% | Morgan Stanley | $167 → $169 | Maintains | Equal-Weight | |||
07/01/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
06/17/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
06/04/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/22/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/16/2024 | -1.81% | RBC Capital | $175 → $175 | Reiterates | Outperform → Outperform | |||
05/06/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
04/18/2024 | -4.62% | HSBC | $169 → $170 | Upgrade | Hold → Buy | |||
04/17/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
04/17/2024 | -6.3% | Morgan Stanley | $168 → $167 | Maintains | Equal-Weight | |||
04/17/2024 | -1.81% | RBC Capital | $181 → $175 | Maintains | Outperform | |||
04/17/2024 | -4.62% | B of A Securities | $180 → $170 | Maintains | Neutral | |||
04/15/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
03/13/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
02/28/2024 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
02/20/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
02/06/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/24/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/24/2024 | 1.55% | RBC Capital | $181 → $181 | Reiterates | Outperform → Outperform | |||
01/24/2024 | -5.18% | Morgan Stanley | $170 → $169 | Maintains | Equal-Weight | |||
01/23/2024 | 20.63% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
01/09/2024 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
01/03/2024 | -1.81% | Raymond James | $172 → $175 | Maintains | Outperform | |||
12/13/2023 | -8.55% | Wells Fargo | $170 → $163 | Downgrade | Overweight → Equal-Weight | |||
12/06/2023 | 1.55% | RBC Capital | $178 → $181 | Maintains | Outperform | |||
12/01/2023 | -0.13% | RBC Capital | $178 → $178 | Reiterates | Outperform → Outperform | |||
12/01/2023 | 0.99% | UBS | → $180 | Upgrade | Neutral → Buy | |||
11/20/2023 | 20.63% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
11/17/2023 | 20.63% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
10/23/2023 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/18/2023 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/18/2023 | -3.5% | Raymond James | $179 → $172 | Maintains | Outperform | |||
10/18/2023 | -4.06% | Morgan Stanley | $174 → $171 | Maintains | Equal-Weight | |||
10/12/2023 | -9.11% | Barclays | $158 → $162 | Maintains | Equal-Weight | |||
10/11/2023 | 20.63% | Cantor Fitzgerald | $215 → $215 | Reiterates | Overweight → Overweight | |||
10/11/2023 | -2.37% | Morgan Stanley | $172 → $174 | Maintains | Equal-Weight | |||
10/09/2023 | 20.63% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight | |||
10/05/2023 | -0.13% | RBC Capital | → $178 | Initiates | → Outperform | |||
10/02/2023 | 20.63% | Cantor Fitzgerald | → $215 | Reiterates | Overweight → Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Johnson & Johnson (JNJ)?
El último precio objetivo de Johnson & Johnson (NYSE:JNJ) fue comunicado por Barclays el julio 17, 2025. La firma de analistas fijó un precio objetivo para $176.00 que espera JNJ a fall dentro de 12 meses (un posible -1.25% downside). 52 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Johnson & Johnson (JNJ)?
La última calificación de analistas para Johnson & Johnson (NYSE:JNJ) fue proporcionada por Barclays, y Johnson & Johnson mantuvo su equal-weight calificación.
¿Cuándo se produjo la última revisión al alza de Johnson & Johnson (JNJ)?
La última revisión al alza de Johnson & Johnson se produjo en abril 9, 2025, cuando Goldman Sachs elevó su precio objetivo a $172. Goldman Sachs anteriormente tenía a neutral para Johnson & Johnson.
¿Cuándo fue la última revisión a la baja de Johnson & Johnson (JNJ)?
La última revisión a la baja de Johnson & Johnson se produjo en mayo 13, 2025, cuando Leerink Partners cambió su precio objetivo de $169 a $153 para Johnson & Johnson.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Johnson & Johnson (JNJ)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Johnson & Johnson, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Johnson & Johnson se registró el julio 17, 2025, por lo que la próxima calificación estará disponible en torno al julio 17, 2026.
¿Es correcta la calificación de los analistas sobre Johnson & Johnson (JNJ)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Johnson & Johnson (JNJ) fue un mantuvo con un precio objetivo de $165.00 a $176.00. El precio actual al que cotiza Johnson & Johnson (JNJ) es de $178.23, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.